Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Oct 24 - Oct 29
This triple agonist approach targets GLP 1, GIP, and glucagon receptors, creating what researchers describe as a synergistic effect on metabolism and appetite regulation
Benefits Significant, clinically proven weight loss Reduced risk of Type 2 diabetes, high blood pressure, and cardiovascular disease Non-surgical, once-weekly injection Personalized dosing not a one-size-fits-all approach Physician-supervised by a board-certified plastic surgeon Built-in path to body contouring if needed after weight loss Best candidates for GLP-1 weight loss injections GLP-1 type medications are suitable for adults who: Have a body mass index (BMI) of 30 or higher (obesity) Have a BMI of 27 or higher (overweight) with at least one weight-related condition, such as type 2 diabetes, high blood pressure, or high cholesterol
Lilly's Phase 2 Retatrutide Results Published in The New England Journal of Medicine Show the Investigational Molecule Achieved up to 17.5% Mean Weight Reduction at 24 Weeks in Adults with Obesity and Overweight
Next, examine the variety of medications available
13.8 per cent did not experience clinically significant weight loss
US$ 23.89
US$ 24.72
US$ 28.04
US$ 23.50
US$ 25.91
